research 0475 High-dose UVA-1 therapy improves patient-reported outcomes and clinical scores in patients with sclerosing skin disease
This study found that high-dose UVA-1 therapy appeared to improve both patient-reported outcomes and objective clinical measures in patients with morphea and systemic sclerosis, supporting its potential efficacy for treating scleroderma.

